ES2131673T3 - Solucion que contiene igf-1. - Google Patents
Solucion que contiene igf-1.Info
- Publication number
- ES2131673T3 ES2131673T3 ES94905282T ES94905282T ES2131673T3 ES 2131673 T3 ES2131673 T3 ES 2131673T3 ES 94905282 T ES94905282 T ES 94905282T ES 94905282 T ES94905282 T ES 94905282T ES 2131673 T3 ES2131673 T3 ES 2131673T3
- Authority
- ES
- Spain
- Prior art keywords
- igf
- mmol
- formulation
- refers
- functional analogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title abstract 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 abstract 4
- 239000000243 solution Substances 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 3
- 230000001105 regulatory effect Effects 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 3
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- 239000007951 isotonicity adjuster Substances 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
LA INVENCION SE REFIERE A SOLUCIONES QUE CONTIENEN IGF-1 O CUALQUIER ANALOGO FUNCIONAL DEL MISMO EN EL QUE EL PH ES DE 5,5 A 6,5, PREFERIBLEMENTE DE 5,7 A 6,2. LA CANTIDAD DE FOSFATO COMO SUSTANCIA REGULADORA DEBERIA ESTAR EN UNA CONCENTRACION MENOR QUE 50 MMOL/L. PREFERIBLEMENTE LA FORMULACION ES UNA SOLUCION ACUOSA DE IGF-1 Y UN FOSFATO COMO SUSTANCIA REGULADORA EN UNA CONCENTRACION DE 5 A 50 MMOL/L O MAS PREFERIBLEMENTE 5-20 MMOL/L, POR EJEMPLO 10 MMOL/L. LA SOLUCION DEBERIA SER ISOTONICA. LA SOLUCION PROPORCIONA UN DOLOR REDUCIDO EN INYECCIONES SUBCUTANEAS. LA INVENCION TAMBIEN SE REFIERE A UN PROCESO PARA LA PREPARACION DE LA FORMULACION MEDIANTE LA MEZCLA DE IGF-1 O CUALQUIER ANALOGO FUNCIONAL DEL MISMO CON UNA SUSTANCIA REGULADORA QUE PROPORCIONA UN PH DE 5,5 A 6,5 Y UN AGENTE ISOTONICO. TAMBIEN SE REFIERE A UN METODO PARA EL TRATAMIENTO DE UN PACIENTE QUE NECESITE IGF-1 O CUALQUIER ANALOGO FUNCIONAL DEL MISMO MEDIANTE LA ADMINISTRACION DE LA FORMULACION REIVINDICADA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9300105A SE9300105D0 (sv) | 1993-01-15 | 1993-01-15 | Stable protein solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2131673T3 true ES2131673T3 (es) | 1999-08-01 |
Family
ID=20388550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94905282T Expired - Lifetime ES2131673T3 (es) | 1993-01-15 | 1994-01-10 | Solucion que contiene igf-1. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5783559A (es) |
| EP (1) | EP0679079B1 (es) |
| JP (1) | JP3580816B2 (es) |
| AT (1) | ATE177942T1 (es) |
| AU (1) | AU676882B2 (es) |
| DE (1) | DE69417397T2 (es) |
| DK (1) | DK0679079T3 (es) |
| ES (1) | ES2131673T3 (es) |
| GR (1) | GR3030383T3 (es) |
| NZ (1) | NZ259951A (es) |
| SE (1) | SE9300105D0 (es) |
| WO (1) | WO1994015584A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9502927D0 (sv) * | 1995-08-24 | 1995-08-24 | Pharmacia Ab | Solution containing IGF-I |
| KR100547402B1 (ko) * | 1996-09-13 | 2006-02-01 | 트랜스케리오틱 쎄러피스, 인코포레이티드 | α-갈락토시다아제 Ａ 결핍을 치료하는 방법 |
| JP2001522814A (ja) * | 1997-11-07 | 2001-11-20 | カイロン コーポレイション | 増大されたｉｇｆ−ｉ溶解性を提供する組成物 |
| US6767892B1 (en) | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
| UY25790A1 (es) * | 1998-11-06 | 2000-08-21 | Bio Sidus S A | Formas farmaceuticas de eritropoyetina humana recombinante estables a temperatura ambiente y apropiadas para su uso en humanos, formulaciones y procedimientos de liofilizacion para su obtencion. |
| BR9917606A (pt) | 1998-11-06 | 2002-12-31 | Bio Sidus S A | Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento |
| US6777205B1 (en) | 1998-11-06 | 2004-08-17 | Sterrenbeld Biotechnologie North America, Inc. | Host cells expressing recombinant human erythropoietin |
| BR9905868A (pt) | 1998-11-06 | 2001-01-23 | Bio Sidus S A | Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento |
| DK1165119T3 (da) | 1999-04-08 | 2003-12-15 | Genentech Inc | Sammensætning baseret på modsat ladede polypeptider |
| JP2001233787A (ja) * | 2000-02-04 | 2001-08-28 | Patents Exploitation Co Bv | 小・中サイズのペプチド含有薬学的組成物 |
| JP5000848B2 (ja) | 2002-05-21 | 2012-08-15 | 第一三共株式会社 | グレリン含有医薬組成物 |
| JP4951344B2 (ja) | 2004-08-24 | 2012-06-13 | 第一三共株式会社 | 生理活性ペプチド液状製剤 |
| US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| JP2020002130A (ja) * | 2018-06-25 | 2020-01-09 | Ｊｃｒファーマ株式会社 | 蛋白質含有水性液剤 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| DE3939346A1 (de) * | 1989-11-29 | 1991-06-06 | Behringwerke Ag | Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
-
1993
- 1993-01-15 SE SE9300105A patent/SE9300105D0/xx unknown
-
1994
- 1994-01-10 EP EP94905282A patent/EP0679079B1/en not_active Expired - Lifetime
- 1994-01-10 DK DK94905282T patent/DK0679079T3/da active
- 1994-01-10 WO PCT/SE1994/000010 patent/WO1994015584A1/en active IP Right Grant
- 1994-01-10 AU AU58939/94A patent/AU676882B2/en not_active Ceased
- 1994-01-10 US US08/491,902 patent/US5783559A/en not_active Expired - Lifetime
- 1994-01-10 AT AT94905282T patent/ATE177942T1/de not_active IP Right Cessation
- 1994-01-10 DE DE69417397T patent/DE69417397T2/de not_active Expired - Fee Related
- 1994-01-10 JP JP51592294A patent/JP3580816B2/ja not_active Expired - Fee Related
- 1994-01-10 ES ES94905282T patent/ES2131673T3/es not_active Expired - Lifetime
- 1994-01-10 NZ NZ259951A patent/NZ259951A/en unknown
-
1999
- 1999-06-01 GR GR990401477T patent/GR3030383T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1994015584A1 (en) | 1994-07-21 |
| EP0679079A1 (en) | 1995-11-02 |
| GR3030383T3 (en) | 1999-09-30 |
| JPH08505617A (ja) | 1996-06-18 |
| DK0679079T3 (da) | 1999-10-11 |
| DE69417397D1 (de) | 1999-04-29 |
| US5783559A (en) | 1998-07-21 |
| NZ259951A (en) | 1996-10-28 |
| ATE177942T1 (de) | 1999-04-15 |
| SE9300105D0 (sv) | 1993-01-15 |
| AU5893994A (en) | 1994-08-15 |
| EP0679079B1 (en) | 1999-03-24 |
| JP3580816B2 (ja) | 2004-10-27 |
| AU676882B2 (en) | 1997-03-27 |
| DE69417397T2 (de) | 1999-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2131673T3 (es) | Solucion que contiene igf-1. | |
| DE3374300D1 (en) | Stabilized activated oxygen and medicaments containing this stabilized activated oxygen | |
| ES2179473T3 (es) | Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local. | |
| DE68914185T2 (de) | Betäubungs- und Feuchtigkeitszusammensetzung und Verfahren zur Herstellung. | |
| ATE287271T1 (de) | Verwendung von vegf zur herstellung eines medikaments zur behandlung oder verhinderung der intimalen hyperplasie und verabreichungsgerät | |
| ES2166783T3 (es) | Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii. | |
| ATE62414T1 (de) | Mittel zur behandlung von herzerkrankungen. | |
| ES2010561A6 (es) | Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina. | |
| RU2002118115A (ru) | Препаративная форма стабильного водного раствора интерферона, способ ее приготовления и использования | |
| ATE200617T1 (de) | Pharmazeutische zusammensetzungen zur transdermalen verabreichung von melatonin und/oder seine analoge | |
| ATE76574T1 (de) | Osmotisches system zur verabreichung von verduennten loesungen. | |
| ATE291918T1 (de) | Kombinationstherapie zur behandlung von tumoren | |
| ES2031462T3 (es) | Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima. | |
| BR9603454A (pt) | Composição e método para tratamento de câncer de próstata | |
| ES2032757T3 (es) | Inyecciones que contienen alcohol poliprenilico y el uso de estas. | |
| US5140008A (en) | Human growth hormone unit dose for the treatment of intoxicated individuals | |
| DE69943240D1 (de) | Verwendung von HGF für die Behandlung von ischämischen Erkrankungen der Extremitäten | |
| DE3775278D1 (de) | Topische methotrexatzubereitung zur behandlung hyperproliferativer epithelerkrankungen. | |
| US4590214A (en) | Method of treatment for herpes | |
| DK1019037T3 (da) | Lægemiddel indeholdende delta-aminolevulinsyre | |
| CA2153787A1 (en) | Solution containing igf-1 | |
| ES2031930T3 (es) | Un metodo para obtener una preparacion liofilizada que contiene aspoxicilina como ingrediente activo. | |
| RU2043103C1 (ru) | Средство, уменьшающее внешнесекреторную недостаточность поджелудочной железы при хроническом панкреатите | |
| RU94026137A (ru) | Способ лечения нейродермита | |
| Kozlov | The effect of carbon dioxide gas on the content of ammonia, glutamine, and urea in the blood of amimals after injection of solutions of ammonium chloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 679079 Country of ref document: ES |